← brief for 2026-09-22 · Slowing decline

A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery

Article No results yet Peer reviewed

Key takeaways

This is a new test of a drug called ilofotase alfa. It aims to stop kidney damage in people having heart surgery. The study is starting, so there are no results yet.

Who did this work

Louis Mourisse (Radboud University Nijmegen) · Marlies Ostermann (King's College London) · Steven Thiessen (Ziekenhuis Oost-Limburg) · Alexander Dumoulin (Inagro (Belgium)) · Alexander P. J. Vlaar (Amsterdam University Medical Centers) · Eric Hoste (Ghent University Hospital) · Selim Mosbahi (University Hospital of Bern) · Antoine Schneider (Centre Hospitalier Universitaire Vaudois) · Alexander Zarbock (University Hospital Münster) · Johannes Boehm (Deutsches Herzzentrum München) · Peter Rosenberger (University of Tübingen) · Matthias Thielmann (West German Heart and Vascular Center Essen)

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-21
https://doi.org/10.1007/s00134-026-08596-y